TAK-861

About Takeda

Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.

Therapeutic Areas

Other Narcolepsy Type 1 (NT1) Drugs